Skip to main content

Two medicines, side by side

Bisoprolol vs losartan

Bisoprolol and losartan are both labeled for high blood pressure. Drugs@FDA records approvals of bisoprolol since 1992 and of losartan since 1995. Pharmacies paid $0.114 per bisoprolol fumarate 5 mg tablet and $0.0327 per losartan potassium 50 mg tablet (NADAC, October 7, 2026); the strengths differ, so the two prices are not like for like. In FDA's classes, bisoprolol is a beta-adrenergic blocker and losartan an angiotensin 2 receptor blocker.

Check it at the source: the bisoprolol FDA label on DailyMed (effective March 11, 2026); the losartan FDA label on DailyMed (effective January 20, 2026).

Highlights of the bisoprolol record

Bisoprolol (Zebeta) · label of March 11, 2026

Used for

From the label: indications

Bisoprolol fumarate tablets are indicated in the management of hypertension. It may be used alone or in combination with other antihypertensive agents.

On the market

Earliest approval on file
July 31, 1992
Generic labelers
24 labelers
Pharmacy cost
$0.114 per tablet

Supply and safety

Shortage
No current entry
Recalls
2

Highlights of the losartan record

Losartan (Cozaar) · label of January 20, 2026

Boxed warning

FETAL TOXICITY When pregnancy is detected, discontinue COZAAR as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions (5.1) ]. WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue COZAAR as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.

Used for

From the label: indications

COZAAR is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. […]

On the market

Earliest approval on file
April 14, 1995
Generic labelers
43 labelers
Pharmacy cost
$0.0327 per tablet

Supply and safety

Shortage
No current entry
Recalls
77

Source: FDA drug labels via openFDA (Bisoprolol label of March 11, 2026, Losartan label of January 20, 2026); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)

How do bisoprolol and losartan differ on the record?

In FDA's classes, bisoprolol is a beta-adrenergic blocker and losartan an angiotensin 2 receptor blocker.

Half-life, in each label's words: Bisoprolol, “The plasma elimination half-life is 9 to 12 hours and is slightly longer in elderly patients, in part because of …”; Losartan, “The terminal half-life of losartan is about 2 hours and of the metabolite is about 6-9 hours.”

Only the losartan label carries a boxed warning.

Generics: bisoprolol since 2000; losartan since 2010 (Drugs@FDA).

BisoprololLosartan
Labeled forHigh blood pressureHigh blood pressure, Chronic kidney disease, Stroke prevention
Pharmacologic classbeta-Adrenergic BlockerAngiotensin 2 Receptor Blocker
How it works (label)n/aAngiotensin II [formed from angiotensin I in a reaction catalyzed by angiotensin converting enzyme (ACE, kininase II)] is a potent vasoconstrictor, the primary vasoactive hormone of the renin-angiotensin system, and an important component …
Half-life (label)The plasma elimination half-life is 9 to 12 hours and is slightly longer in elderly patients, in part because of decreased renal function in that population.The terminal half-life of losartan is about 2 hours and of the metabolite is about 6-9 hours.
Earliest approval on file (Drugs@FDA)July 31, 1992April 14, 1995
First generic approvedNovember 16, 2000April 6, 2010
Generic labelers (NDC)24 labelers43 labelers
Pharmacy cost (NADAC, each one's most listed form; strengths differ)$0.114 per tablet (Bisoprolol fumarate 5 mg tablet)$0.0327 per tablet (Losartan potassium 50 mg tablet)
12-month price change-39%+2%
Boxed warningNoYes
Shortage nowNo current entryNo current entry
Recalls recorded277
FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used)135,060200,566
DEA schedulenonenone

Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)

What next?

Alternatives to bisoprolol
every medicine labeled for the same conditions